Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over with Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs

Next Previous
Trial Profile

A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over with Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonelokimab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms IZAR-1
  • Sponsors MoonLake Immunotherapeutics

Most Recent Events

  • 03 Dec 2024 Status changed from not yet recruiting to recruiting.
  • 13 Nov 2024 According to a MoonLake Immunotherapeutics media release, the initiation of this Phase 3 program follows the announcement in June 2024 of the successful outcome of MoonLake's end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), as well as positive feedback from its interactions with the European Medicines Agency (EMA).
  • 13 Nov 2024 According to a MoonLake Immunotherapeutics media release, readout of the primary endpoint is anticipated in H1 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top